Key TakeawaysExact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential. Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook. The company reported a third-quarter net loss of $38.2 million or 21 cents p ...